search
Back to results

MR Guided Focused Ultrasound Surgery in the Treatment of Uterine Fibroids: Software V4.2 Validation

Primary Purpose

Uterine Fibroids, Uterine Leiomyomas

Status
Completed
Phase
Phase 3
Locations
United States
Study Type
Interventional
Intervention
ExAblate 2000
Sponsored by
InSightec
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Uterine Fibroids focused on measuring Fibroids, Uterine Leiomyomas, ExAblate, MrgFUS

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)FemaleAccepts Healthy Volunteers

Inclusion Criteria: Women who present with symptomatic uterine fibroids and are not seeking treatment for the reason of improving fertility. Able and willing to give consent and able to attend all study visits. Patient is pre or peri-menopausal (within 12 months of last menstrual period). Able to communicate sensations during the ExAblate procedure. Uterine fibroids, which are device accessible (i.e., positioned in the uterus such that they can be accessed without being shielded by bowel or bone). Fibroids(s) clearly visible on non-contrast MRI. Exclusion Criteria: Metallic implants that are incompatible with MRI Sensitive to MRI contrast agents Severe claustrophobia that would prevent completion of procedure in MR unit Who are pregnant or desire to become pregnant in the future. Pregnancies following ExAblate treatment could be dangerous for both mother and fetus. Pedunculated fibroids Active pelvic inflammatory disease (PID) Active local or systemic infection Known or suspected pelvic carcinoma or pre-malignant conditions, including sarcoma and adenomatous hyperplasia Intrauterine device (IUD) anywhere in the treatment path Dermoid cyst of the ovary anywhere in the treatment path Extensive abdominal scarring that cannot be avoided by redirection of the beam (e.g., due to Caesarean section or repeated abdominal surgeries) Undiagnosed vaginal bleeding

Sites / Locations

  • University of California at San Diego
  • Lahey Clinic
  • KNI
  • Cornell Vascular

Outcomes

Primary Outcome Measures

In this IDE for the 4.2 ExAblate system, the goal is evaluation of the new features to confirm that they do not introduce any new safety issues.

Secondary Outcome Measures

Full Information

First Posted
February 21, 2006
Last Updated
December 19, 2018
Sponsor
InSightec
search

1. Study Identification

Unique Protocol Identification Number
NCT00295217
Brief Title
MR Guided Focused Ultrasound Surgery in the Treatment of Uterine Fibroids: Software V4.2 Validation
Official Title
MR Guided Focused Ultrasound Surgery in the Treatment of Uterine Fibroids: Clinical Study to Validate the Changes to ExAblate 2000 Device
Study Type
Interventional

2. Study Status

Record Verification Date
December 2018
Overall Recruitment Status
Completed
Study Start Date
February 2006 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
October 2006 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
InSightec

4. Oversight

5. Study Description

Brief Summary
The goal of this study is to validate the new ExAblate Application software V4.2 by developing additional data that shows the safety of this treatment. The ExAblate is intended to ablate uterine fibroid tissue in pre- or peri-menopausal women with symptomatic uterine fibroids who desire a uterine sparing procedure. Patients must have a uterine size of less than 24 weeks and not seeking treatment for reasons of improving fertility.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Uterine Fibroids, Uterine Leiomyomas
Keywords
Fibroids, Uterine Leiomyomas, ExAblate, MrgFUS

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
15 (false)

8. Arms, Groups, and Interventions

Intervention Type
Device
Intervention Name(s)
ExAblate 2000
Primary Outcome Measure Information:
Title
In this IDE for the 4.2 ExAblate system, the goal is evaluation of the new features to confirm that they do not introduce any new safety issues.

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Women who present with symptomatic uterine fibroids and are not seeking treatment for the reason of improving fertility. Able and willing to give consent and able to attend all study visits. Patient is pre or peri-menopausal (within 12 months of last menstrual period). Able to communicate sensations during the ExAblate procedure. Uterine fibroids, which are device accessible (i.e., positioned in the uterus such that they can be accessed without being shielded by bowel or bone). Fibroids(s) clearly visible on non-contrast MRI. Exclusion Criteria: Metallic implants that are incompatible with MRI Sensitive to MRI contrast agents Severe claustrophobia that would prevent completion of procedure in MR unit Who are pregnant or desire to become pregnant in the future. Pregnancies following ExAblate treatment could be dangerous for both mother and fetus. Pedunculated fibroids Active pelvic inflammatory disease (PID) Active local or systemic infection Known or suspected pelvic carcinoma or pre-malignant conditions, including sarcoma and adenomatous hyperplasia Intrauterine device (IUD) anywhere in the treatment path Dermoid cyst of the ovary anywhere in the treatment path Extensive abdominal scarring that cannot be avoided by redirection of the beam (e.g., due to Caesarean section or repeated abdominal surgeries) Undiagnosed vaginal bleeding
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
George Holland, M.D.
Organizational Affiliation
Lahey Clinic
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Mark Shaman, M.D.
Organizational Affiliation
KNI
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Robert Min, M.D.
Organizational Affiliation
Cornell
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Anne Roberts, M.D.
Organizational Affiliation
University of California, San Diego
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of California at San Diego
City
La Jolla
State/Province
California
ZIP/Postal Code
92037
Country
United States
Facility Name
Lahey Clinic
City
Burlington
State/Province
Massachusetts
ZIP/Postal Code
01805
Country
United States
Facility Name
KNI
City
Kalamazoo
State/Province
Michigan
ZIP/Postal Code
49048
Country
United States
Facility Name
Cornell Vascular
City
New York
State/Province
New York
ZIP/Postal Code
10022
Country
United States

12. IPD Sharing Statement

Links:
URL
http://www.insightec.com
Description
Sponsor web page

Learn more about this trial

MR Guided Focused Ultrasound Surgery in the Treatment of Uterine Fibroids: Software V4.2 Validation

We'll reach out to this number within 24 hrs